RJA
GLMD icon

Raymond James & Associates’s Galmed Pharmaceuticals GLMD Stock Holding History

Raymond James & Associates’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-96
Closed -$58.9K – 3888
2023
Q1 		$58.9K Hold
96
– – ﹤0.01% 3719
2022
Q4 		$69K Sell
96
-12
-11% -$6.29K ﹤0.01% 3691
2022
Q3 		$49K Sell
108
-1
-0.9% -$683 ﹤0.01% 3708
2022
Q2 		$102K Sell
109
-32
-23% -$42.4K ﹤0.01% 3676
2022
Q1 		$323K Hold
141
– – ﹤0.01% 3370
2021
Q4 		$370K Sell
141
-18
-11% -$65K ﹤0.01% 3313
2021
Q3 		$641K Buy
159
+15
+10% +$62.9K ﹤0.01% 2883
2021
Q2 		$632K Buy
144
+41
+40% +$178K ﹤0.01% 2916
2021
Q1 		$511K Buy
103
+6
+6% +$33.2K ﹤0.01% 3001
2020
Q4 		$437K Sell
97
-62
-39% -$310K ﹤0.01% 2905
2020
Q3 		$807K Sell
159
-212
-57% -$1.38M ﹤0.01% 2308
2020
Q2 		$2.56M Buy
371
+132
+55% +$891K ﹤0.01% 1575
2020
Q1 		$1.19M Sell
239
-41
-15% -$312K ﹤0.01% 1864
2019
Q4 		$2.33M Buy
280
+103
+58% +$708K ﹤0.01% 1736
2019
Q3 		$1.22M Buy
177
+98
+124% +$786K ﹤0.01% 2072
2019
Q2 		$838K Buy
79
+18
+30% +$186K ﹤0.01% 2329
2019
Q1 		$713K Buy
61
+1
+2% +$11.6K ﹤0.01% 2407
2018
Q4 		$589K Buy
60
+10
+20% +$140K ﹤0.01% 2445
2018
Q3 		$984K Buy
+50
New +$936K ﹤0.01% 2268

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TFGT
TS Financial Group (TSFG) Lake Forest, Illinois $794M AUM 24.65% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BCM
Bourgeon Capital Management Darien, Connecticut $679M AUM 50.89% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Raymond James & Associates's GLMD Position: Q2 2023 in Review

Raymond James & Associates sold out of Galmed Pharmaceuticals (GLMD) in Q2 2023, closing a stake of 96 shares — an estimated $58.9K sold.

Raymond James & Associates first reported a position in GLMD in Q3 2018 and held it in 19 quarters. The position peaked at $2.56M in Q2 2020. 8 funds tracked by Wall St. Rank hold GLMD as of Q2 2023.

  • Raymond James & Associates reported no remaining Galmed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 96 Galmed Pharmaceuticals shares in Q2 2023, an estimated $58.9K.
  • Raymond James & Associates first reported a position in Galmed Pharmaceuticals in Q3 2018 and held it in 19 quarters.
  • Raymond James & Associates's Galmed Pharmaceuticals position peaked at $2.56M in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.